Postoperative surveillance of main duct IPMN

Takao Ohtsuka, Masao Tanaka

研究成果: 著書/レポートタイプへの貢献

抄録

Surveillance schedule after resection of main duct IPMNs (MD-IPMNs) is determined based on pathological grade and surgical margin status. Prognosis after resection of invasive IPMNs is better than that of conventional pancreatic ductal adenocarcinomas (PDACs) in the matched status of T1 or N0, or the subtype of colloid carcinoma, while it is not different from that of PDACs in the other conditions (T2 to T4, N1, or other subtypes of carcinoma). Thus, the patients with invasive MD-IPMNs should be basically surveyed according to the protocol of the PDACs. In noninvasive IPMNs (low- to intermediate-grade dysplasia), if there is no residual lesion in the remnant pancreas with negative surgical margin, then the patients might be surveyed at 2 and 5 years after operation to check the development of new lesions in the remnant pancreas. In the patients having positive surgical margin of low- to intermediate-grade dysplasia, the surveillance of twice a year using physical examination and magnetic resonance imaging (MRI) might be suitable, although there has been no evidence regarding the effect of this protocol. On the other hand, it remains unclear whether this surveillance protocol of twice a year would be also applied to the patients after resection for noninvasive carcinoma (high-grade dysplasia). If there are some clinical signs to suspect the progression of the diseases in such patients, then surveillance with shorter interval is recommended.

元の言語英語
ホスト出版物のタイトルIntraductal Papillary Mucinous Neoplasm of the Pancreas
出版者Springer Japan
ページ181-188
ページ数8
9784431544722
ISBN(電子版)9784431544722
ISBN(印刷物)4431544712, 9784431544715
DOI
出版物ステータス出版済み - 11 1 2014

Fingerprint

Adenocarcinoma
Pancreas
Carcinoma
Mucinous Adenocarcinoma
Physical Examination
Disease Progression
Appointments and Schedules
Magnetic Resonance Imaging
Margins of Excision

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Ohtsuka, T., & Tanaka, M. (2014). Postoperative surveillance of main duct IPMN. : Intraductal Papillary Mucinous Neoplasm of the Pancreas (巻 9784431544722, pp. 181-188). Springer Japan. https://doi.org/10.1007/978-4-431-54472-2_15

Postoperative surveillance of main duct IPMN. / Ohtsuka, Takao; Tanaka, Masao.

Intraductal Papillary Mucinous Neoplasm of the Pancreas. 巻 9784431544722 Springer Japan, 2014. p. 181-188.

研究成果: 著書/レポートタイプへの貢献

Ohtsuka, T & Tanaka, M 2014, Postoperative surveillance of main duct IPMN. : Intraductal Papillary Mucinous Neoplasm of the Pancreas. 巻. 9784431544722, Springer Japan, pp. 181-188. https://doi.org/10.1007/978-4-431-54472-2_15
Ohtsuka T, Tanaka M. Postoperative surveillance of main duct IPMN. : Intraductal Papillary Mucinous Neoplasm of the Pancreas. 巻 9784431544722. Springer Japan. 2014. p. 181-188 https://doi.org/10.1007/978-4-431-54472-2_15
Ohtsuka, Takao ; Tanaka, Masao. / Postoperative surveillance of main duct IPMN. Intraductal Papillary Mucinous Neoplasm of the Pancreas. 巻 9784431544722 Springer Japan, 2014. pp. 181-188
@inbook{4af32733f8d54aad878a1fc3dfbd22e0,
title = "Postoperative surveillance of main duct IPMN",
abstract = "Surveillance schedule after resection of main duct IPMNs (MD-IPMNs) is determined based on pathological grade and surgical margin status. Prognosis after resection of invasive IPMNs is better than that of conventional pancreatic ductal adenocarcinomas (PDACs) in the matched status of T1 or N0, or the subtype of colloid carcinoma, while it is not different from that of PDACs in the other conditions (T2 to T4, N1, or other subtypes of carcinoma). Thus, the patients with invasive MD-IPMNs should be basically surveyed according to the protocol of the PDACs. In noninvasive IPMNs (low- to intermediate-grade dysplasia), if there is no residual lesion in the remnant pancreas with negative surgical margin, then the patients might be surveyed at 2 and 5 years after operation to check the development of new lesions in the remnant pancreas. In the patients having positive surgical margin of low- to intermediate-grade dysplasia, the surveillance of twice a year using physical examination and magnetic resonance imaging (MRI) might be suitable, although there has been no evidence regarding the effect of this protocol. On the other hand, it remains unclear whether this surveillance protocol of twice a year would be also applied to the patients after resection for noninvasive carcinoma (high-grade dysplasia). If there are some clinical signs to suspect the progression of the diseases in such patients, then surveillance with shorter interval is recommended.",
author = "Takao Ohtsuka and Masao Tanaka",
year = "2014",
month = "11",
day = "1",
doi = "10.1007/978-4-431-54472-2_15",
language = "English",
isbn = "4431544712",
volume = "9784431544722",
pages = "181--188",
booktitle = "Intraductal Papillary Mucinous Neoplasm of the Pancreas",
publisher = "Springer Japan",
address = "Japan",

}

TY - CHAP

T1 - Postoperative surveillance of main duct IPMN

AU - Ohtsuka, Takao

AU - Tanaka, Masao

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Surveillance schedule after resection of main duct IPMNs (MD-IPMNs) is determined based on pathological grade and surgical margin status. Prognosis after resection of invasive IPMNs is better than that of conventional pancreatic ductal adenocarcinomas (PDACs) in the matched status of T1 or N0, or the subtype of colloid carcinoma, while it is not different from that of PDACs in the other conditions (T2 to T4, N1, or other subtypes of carcinoma). Thus, the patients with invasive MD-IPMNs should be basically surveyed according to the protocol of the PDACs. In noninvasive IPMNs (low- to intermediate-grade dysplasia), if there is no residual lesion in the remnant pancreas with negative surgical margin, then the patients might be surveyed at 2 and 5 years after operation to check the development of new lesions in the remnant pancreas. In the patients having positive surgical margin of low- to intermediate-grade dysplasia, the surveillance of twice a year using physical examination and magnetic resonance imaging (MRI) might be suitable, although there has been no evidence regarding the effect of this protocol. On the other hand, it remains unclear whether this surveillance protocol of twice a year would be also applied to the patients after resection for noninvasive carcinoma (high-grade dysplasia). If there are some clinical signs to suspect the progression of the diseases in such patients, then surveillance with shorter interval is recommended.

AB - Surveillance schedule after resection of main duct IPMNs (MD-IPMNs) is determined based on pathological grade and surgical margin status. Prognosis after resection of invasive IPMNs is better than that of conventional pancreatic ductal adenocarcinomas (PDACs) in the matched status of T1 or N0, or the subtype of colloid carcinoma, while it is not different from that of PDACs in the other conditions (T2 to T4, N1, or other subtypes of carcinoma). Thus, the patients with invasive MD-IPMNs should be basically surveyed according to the protocol of the PDACs. In noninvasive IPMNs (low- to intermediate-grade dysplasia), if there is no residual lesion in the remnant pancreas with negative surgical margin, then the patients might be surveyed at 2 and 5 years after operation to check the development of new lesions in the remnant pancreas. In the patients having positive surgical margin of low- to intermediate-grade dysplasia, the surveillance of twice a year using physical examination and magnetic resonance imaging (MRI) might be suitable, although there has been no evidence regarding the effect of this protocol. On the other hand, it remains unclear whether this surveillance protocol of twice a year would be also applied to the patients after resection for noninvasive carcinoma (high-grade dysplasia). If there are some clinical signs to suspect the progression of the diseases in such patients, then surveillance with shorter interval is recommended.

UR - http://www.scopus.com/inward/record.url?scp=84930909414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930909414&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-54472-2_15

DO - 10.1007/978-4-431-54472-2_15

M3 - Chapter

AN - SCOPUS:84930909414

SN - 4431544712

SN - 9784431544715

VL - 9784431544722

SP - 181

EP - 188

BT - Intraductal Papillary Mucinous Neoplasm of the Pancreas

PB - Springer Japan

ER -